• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

确定慢性偏头痛头痛影响测试(HIT-6)总分和项目特异性评分的有意义变化阈值。

Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT-6) Total and Item-Specific Scores in Chronic Migraine.

机构信息

Vector Psychometric Group, LLC, Chapel Hill, NC, USA.

Neurology, Lundbeck Seattle BioPharmaceuticals, Inc., Bothell, WA, USA.

出版信息

Headache. 2020 Oct;60(9):2003-2013. doi: 10.1111/head.13946. Epub 2020 Aug 30.

DOI:10.1111/head.13946
PMID:32862469
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7693226/
Abstract

OBJECTIVE

The objective of the analyses described here was to develop thresholds defining clinically meaningful response on the total and item scores of the 6-item short-form Headache Impact Test (HIT-6) in a population of patients with chronic migraine (CM).

BACKGROUND

The HIT-6 is a short, easily understood, and useful measure of the impact of headache on daily life. Though widely used, limited literature supports a threshold value for clinically meaningful response within individuals over time for the HIT-6 total score and for the item scores, especially in the CM population.

METHODS

PROMISE-2 is a randomized, double-blind, multicenter study comparing intravenous eptinezumab 100 and 300 mg with placebo for the preventive treatment of CM. Responder definitions for HIT-6 total and items scores using data from PROMISE-2 study were calculated via distribution-based and anchor-based methods. Distribution-based methods included half of the baseline standard deviation and baseline standard error of measurement. The change from baseline to week 12 in HIT-6 scores was assessed using the following anchors: patient global impression of change, reduction in migraine frequency, and change in EuroQol 5 dimensions 5 levels visual analog scale. Values from the literature and PROMISE-2 analyses were plotted against the cumulative distribution function of change values (baseline to week 12) and used to triangulate to empirically support clinically meaningful change definitions for the HIT-6 total and item scores in patients with CM.

RESULTS

From the literature, 5 articles provided 7 candidate values for a responder threshold for the HIT-6 total score. From distribution- and anchor-based methods, 5 candidate values were derived from PROMISE-2 data. Using the median of all candidate values, a HIT-6 total score responder definition estimate of -6 (ie, ≥6-point improvement in the total score) appears most appropriate for discriminating between individuals with CM who have experienced meaningful change over time and those who have not. For item-level analyses using anchor-based methods, the responder definition for items 1-3 ("severe pain," "limits daily activities," and "lie down") was a 1-category improvement in response (eg, from Sometimes to Rarely); for items 4-6 ("too tired," "felt fed up or irritated," and "limits concentration"), a 2-category improvement in response (eg, from Always to Sometimes) was clinically meaningful.

CONCLUSIONS

Using a multifaceted, statistically-based approach, the recommended responder definition for the HIT-6 total score in the CM population is a ≥6-point decrease, consistent with previous literature. Anchor-based item-level responder thresholds were defined as a decrease of 1 or 2 categories, depending on the item. These CM-specific values will provide researchers and clinicians a means to interpret clinically meaningful change in the HIT-6 total and item scores and may facilitate the measurement of treatment benefits in specific functional domains of the HIT-6.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6b6/7693226/1200f635a875/HEAD-60-2003-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6b6/7693226/f1817671b76a/HEAD-60-2003-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6b6/7693226/36c4076d8dfd/HEAD-60-2003-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6b6/7693226/1200f635a875/HEAD-60-2003-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6b6/7693226/f1817671b76a/HEAD-60-2003-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6b6/7693226/36c4076d8dfd/HEAD-60-2003-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6b6/7693226/1200f635a875/HEAD-60-2003-g003.jpg
摘要

目的

本文分析旨在为慢性偏头痛(CM)患者人群制定 6 项简短头痛影响测试(HIT-6)总分和各项目得分的临床有意义应答阈值。

背景

HIT-6 是一种简短、易于理解且对日常生活中头痛影响有用的衡量标准。尽管应用广泛,但对于 HIT-6 总分和各项目得分的个体内随时间变化的临床有意义应答阈值,仅有有限的文献支持,特别是在 CM 人群中。

方法

PROMISE-2 是一项随机、双盲、多中心研究,比较了依替唑仑单抗 100mg 和 300mg 与安慰剂在 CM 的预防性治疗中的效果。通过分布基础和锚定基础方法,使用 PROMISE-2 研究的数据计算了 HIT-6 总分和各项目得分的应答定义。分布基础方法包括基线标准差的一半和测量的基线标准误差。使用以下锚定物评估 HIT-6 评分从基线到第 12 周的变化:患者整体印象变化、偏头痛频率降低和 EuroQol 5 维度 5 级视觉模拟量表变化。从文献和 PROMISE-2 分析中获取的值与变化值(从基线到第 12 周)的累积分布函数进行对比,并用于三角测量,以实证支持 CM 患者 HIT-6 总分和各项目得分的临床有意义变化定义。

结果

从文献中,5 篇文章提供了 7 个 HIT-6 总分应答阈值的候选值。从分布基础和锚定基础方法中,从 PROMISE-2 数据中得出了 5 个候选值。使用所有候选值的中位数,HIT-6 总分应答定义估计值为-6(即总分提高≥6 分),这似乎最适合区分 CM 患者中随时间经历有意义变化的个体和未经历有意义变化的个体。对于使用锚定基础方法的项目水平分析,项目 1-3(“严重疼痛”、“限制日常活动”和“躺下”)的应答定义为 1 类改善(例如,从有时到很少);对于项目 4-6(“太累”、“感到厌烦或恼怒”和“限制注意力”),2 类改善(例如,从不总是到有时)在临床上是有意义的。

结论

使用多方面的、基于统计学的方法,CM 人群中 HIT-6 总分的推荐应答定义为≥6 分的下降,与之前的文献一致。基于锚定的项目水平应答阈值定义为 1 类或 2 类的下降,具体取决于项目。这些 CM 特定的值将为研究人员和临床医生提供一种解释 HIT-6 总分和各项目得分的临床有意义变化的方法,并可能有助于衡量 HIT-6 特定功能领域的治疗效果。

相似文献

1
Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT-6) Total and Item-Specific Scores in Chronic Migraine.确定慢性偏头痛头痛影响测试(HIT-6)总分和项目特异性评分的有意义变化阈值。
Headache. 2020 Oct;60(9):2003-2013. doi: 10.1111/head.13946. Epub 2020 Aug 30.
2
Psychometric validation and meaningful within-patient change of the Migraine-Specific Quality of Life questionnaire version 2.1 electronic patient-reported outcome in patients with episodic and chronic migraine.偏头痛特异性生活质量问卷 2.1 电子患者报告结局在发作性和慢性偏头痛患者中的心理测量验证和有意义的患者内变化。
Headache. 2021 Mar;61(3):511-526. doi: 10.1111/head.14031. Epub 2021 Jan 22.
3
Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine.偏头痛头痛日缓解率及其对患者功能的影响:加奈珠单抗治疗偏头痛患者的 3 项随机 3 期临床试验评估。
Headache. 2020 Nov;60(10):2304-2319. doi: 10.1111/head.14013.
4
Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study.依普替扎umab 治疗在偏头痛发作期间开始与患者报告的结局测量指标的显著改善相关:随机对照 RELIEF 研究的次要结果。
J Headache Pain. 2022 Feb 7;23(1):22. doi: 10.1186/s10194-021-01376-7.
5
Psychometric Validation of the Role Function Restrictive Domain of the Migraine Specific Quality-of-Life Questionnaire Version 2.1 Electronic Patient-Reported Outcome in Patients With Episodic and Chronic Migraine.偏头痛特异性生活质量问卷 2.1 版角色功能受限维度的心理计量学验证:在发作性和慢性偏头痛患者中的电子患者报告结局。
Headache. 2019 May;59(5):756-774. doi: 10.1111/head.13497. Epub 2019 Mar 12.
6
Eptinezumab improved patient-reported outcomes in patients with migraine and medication-overuse headache: Subgroup analysis of the randomized PROMISE-2 trial.依替唑仑单抗改善偏头痛和药物过度使用性头痛患者的患者报告结局:随机 PROMISE-2 试验的亚组分析。
Headache. 2023 Feb;63(2):264-274. doi: 10.1111/head.14434. Epub 2023 Jan 12.
7
Reliability and validity of the 6-item Headache Impact Test in chronic migraine from the PROMISE-2 study.PROMISE-2 研究中慢性偏头痛患者 6 项头痛影响测试的信度和效度。
Qual Life Res. 2021 Mar;30(3):931-943. doi: 10.1007/s11136-020-02668-2. Epub 2020 Oct 20.
8
Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2.依替唑仑单抗治疗慢性偏头痛合并药物过度使用性头痛双重诊断患者的疗效、耐受性和安全性:PROMISE-2 的亚组分析。
Headache. 2021 Jan;61(1):125-136. doi: 10.1111/head.14036. Epub 2020 Dec 13.
9
Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials.在对eptinezumab 有≥75%应答的患者中,患者报告结局、健康相关生活质量和急性药物使用:PROMISE 试验的亚组汇总分析。
J Headache Pain. 2022 Feb 7;23(1):23. doi: 10.1186/s10194-022-01386-z.
10
Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache.依替班特预防偏头痛治疗可使慢性偏头痛和药物过度使用性头痛患者的急性头痛药物和头痛发作频率降低至诊断阈值以下。
Headache. 2021 Oct;61(9):1421-1431. doi: 10.1111/head.14206. Epub 2021 Sep 22.

引用本文的文献

1
Disrupting Migraine Dynamics: A Narrative Review of the Consequences of Modern Anti-CGRP Monoclonal Antibody Therapies.扰乱偏头痛动态:现代抗降钙素基因相关肽单克隆抗体疗法后果的叙述性综述
Neurol Ther. 2025 May 27. doi: 10.1007/s40120-025-00769-z.
2
Clinical characteristics and short-term outcomes of migraine with patent foramen ovale: a comparative study.卵圆孔未闭型偏头痛的临床特征及短期预后:一项对比研究。
Eur J Med Res. 2025 May 20;30(1):400. doi: 10.1186/s40001-025-02645-w.
3
A randomized crossover trial: The impact of ocular lubrication on migraine severity in persons with dry eye disease and migraine.

本文引用的文献

1
Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2.依替班巴治疗慢性偏头痛患者的疗效和安全性:PROMISE-2 研究。
Neurology. 2020 Mar 31;94(13):e1365-e1377. doi: 10.1212/WNL.0000000000009169. Epub 2020 Mar 24.
2
CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta-analysis.降钙素基因相关肽单克隆抗体用于慢性偏头痛的预防性治疗:荟萃分析更新。
Brain Behav. 2019 Feb;9(2):e01215. doi: 10.1002/brb3.1215. Epub 2019 Jan 18.
3
The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice.
一项随机交叉试验:眼部润滑对干眼症合并偏头痛患者偏头痛严重程度的影响。
Optom Vis Sci. 2025 Apr 1;102(4):183-188. doi: 10.1097/OPX.0000000000002241. Epub 2025 Feb 24.
4
Eptinezumab treatment was associated with longer interictal headache/migraine periods which corresponded to greater improvements in patient-reported quality of life measures.艾普奈珠单抗治疗与更长的发作间期头痛/偏头痛期相关,这与患者报告的生活质量指标的更大改善相对应。
J Neurol. 2024 Dec 12;272(1):4. doi: 10.1007/s00415-024-12809-z.
5
Real-World Experience of Erenumab in Patients with Migraine in Germany: The SPECTRE Study.依瑞奈尤单抗在德国偏头痛患者中的真实世界经验:SPECTRE研究
Pain Ther. 2024 Dec;13(6):1659-1678. doi: 10.1007/s40122-024-00658-7. Epub 2024 Oct 21.
6
Multimodal digital health treatments for Chronic Migraine associated with Medication Overuse Headache: a literature appraisal and results of a single-arm open trial (the BE-HOME program).多模态数字化健康治疗慢性偏头痛伴药物过度使用性头痛:文献评价和单臂开放试验结果(BE-HOME 项目)。
Neurol Sci. 2024 Oct;45(10):4923-4930. doi: 10.1007/s10072-024-07568-8. Epub 2024 May 21.
7
Calcitonin gene-related peptide: a possible biomarker in migraine patients with patent foramen ovale.降钙素基因相关肽:卵圆孔未闭偏头痛患者的一个可能的生物标志物。
BMC Neurol. 2024 Apr 16;24(1):126. doi: 10.1186/s12883-024-03615-1.
8
Observational Retrospective Study in Patients Treated with Galcanezumab as Preventive Treatment for Migraine: The ORYGAM Study.加卡尼单抗预防性治疗偏头痛患者的观察性回顾性研究:ORYGAM研究
Pain Ther. 2024 Jun;13(3):557-576. doi: 10.1007/s40122-024-00586-6. Epub 2024 Mar 28.
9
Anti-CGRP and Anti-CGRP Receptor Monoclonal Antibodies for Migraine Prophylaxis: Retrospective Observational Study on 209 Patients.用于偏头痛预防的抗降钙素基因相关肽和抗降钙素基因相关肽受体单克隆抗体:对209例患者的回顾性观察研究
J Clin Med. 2024 Feb 17;13(4):1130. doi: 10.3390/jcm13041130.
10
Minimal Clinically Important Difference (MCID) in Patient-Reported Outcome Measures for Neurological Conditions: Review of Concept and Methods.神经疾病患者报告结局测量中的最小临床重要差异(MCID):概念与方法综述
Ann Indian Acad Neurol. 2023 Jul-Aug;26(4):334-343. doi: 10.4103/aian.aian_207_23. Epub 2023 Jun 12.
美国头痛学会关于将新的偏头痛治疗方法纳入临床实践的立场声明。
Headache. 2019 Jan;59(1):1-18. doi: 10.1111/head.13456. Epub 2018 Dec 10.
4
Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab.发作性偏头痛患者的功能测量:加奈徳珠单抗的一项双盲、随机、安慰剂对照 2b 期试验结果。
Headache. 2018 Sep;58(8):1225-1235. doi: 10.1111/head.13383. Epub 2018 Aug 14.
5
Qualitative Change in Migraine Prevention?偏头痛预防的质变?
Headache. 2018 Jul;58(7):1092-1095. doi: 10.1111/head.13354. Epub 2018 Jul 23.
6
Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults.国际头痛学会成人慢性偏头痛预防性治疗对照试验指南。
Cephalalgia. 2018 Apr;38(5):815-832. doi: 10.1177/0333102418758283. Epub 2018 Mar 4.
7
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.国际头痛协会(IHS)头痛分类委员会《国际头痛疾病分类》第三版
Cephalalgia. 2018 Jan;38(1):1-211. doi: 10.1177/0333102417738202.
8
Family Impact of Migraine: Development of the Impact of Migraine on Partners and Adolescent Children (IMPAC) Scale.偏头痛对家庭的影响:偏头痛对伴侣及青少年子女影响量表(IMPAC)的编制
Headache. 2017 Apr;57(4):570-585. doi: 10.1111/head.13028. Epub 2017 Feb 10.
9
Measuring the impact of migraine for evaluating outcomes of preventive treatments for migraine headaches.测量偏头痛的影响以评估偏头痛预防性治疗的效果。
Health Qual Life Outcomes. 2016 Oct 6;14(1):143. doi: 10.1186/s12955-016-0542-3.
10
A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache-Related Disability.慢性偏头痛流行病学与转归(CaMEO)研究和美国偏头痛患病率与预防(AMPP)研究的比较:人口统计学和头痛相关残疾情况
Headache. 2016 Sep;56(8):1280-9. doi: 10.1111/head.12878. Epub 2016 Jun 28.